Weiland O - Search Results

1

Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response.

Werner M, Wallerstedt S, Lindgren S, Almer S, Björnsson E, Bergquist A, Prytz H, Sandberg-Gertzén H, Hultcrantz R, Sangfelt P, Weiland O, Ohlsson B, Danielsson A. Werner M, et al. Among authors: weiland o. Scand J Gastroenterol. 2010 Apr;45(4):457-67. doi: 10.3109/00365520903555861. Scand J Gastroenterol. 2010. PMID: 20082594

2

Antibodies to recombinant and synthetic peptides derived from the hepatitis C virus genome in long-term-studied patients with posttransfusion hepatitis C.

Mattsson L, Gutierrez RA, Dawson GJ, Lesniewski RR, Mushahwar LK, Weiland O. Mattsson L, et al. Among authors: weiland o. Scand J Gastroenterol. 1991 Dec;26(12):1257-62. doi: 10.3109/00365529108998622. Scand J Gastroenterol. 1991. PMID: 1722348

3

Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B/C hepatitis: long-term outcome and effect of increased interferon doses in non-responders.

Schvarcz R, Glaumann H, Weiland O, Norkrans G, Wejstål R, Frydén A. Schvarcz R, et al. Among authors: weiland o. Scand J Infect Dis. 1991;23(4):413-20. doi: 10.3109/00365549109075088. Scand J Infect Dis. 1991. PMID: 1957127 Clinical Trial.

4

Autoimmune chronic active hepatitis: changing reactivity for antibodies to hepatitis C virus after immunosuppressive treatment.

Schvarcz R, von Sydow M, Weiland O. Schvarcz R, et al. Among authors: weiland o. Scand J Gastroenterol. 1990 Nov;25(11):1175-80. doi: 10.3109/00365529008998551. Scand J Gastroenterol. 1990. PMID: 2177220

5

[New therapeutic possibilities in fulminant viral hepatitis].

Weiland O, Ericzon BG, Andersson J, Hultcrantz R, Stiernstedt G. Weiland O, et al. Lakartidningen. 1989 Mar 1;86(9):727-9. Lakartidningen. 1989. PMID: 2522162 Swedish. No abstract available.

6

Long-term histological outcome in patients with chronic hepatitis C treated repeatedly with interferon alpha-2b without sustained response.

Reichard O, Glaumann H, Weiland O. Reichard O, et al. Among authors: weiland o. Scand J Infect Dis. 1994;26(4):383-9. doi: 10.3109/00365549409008609. Scand J Infect Dis. 1994. PMID: 7984968 Clinical Trial.

7

Hepatitis E virus infections in patients with acute hepatitis non-A-D in Sweden.

Johansson PJ, Mushahwar IK, Norkrans G, Weiland O, Nordenfelt E. Johansson PJ, et al. Among authors: weiland o. Scand J Infect Dis. 1995;27(6):543-6. doi: 10.3109/00365549509047064. Scand J Infect Dis. 1995. PMID: 8685630

8

Factors influencing the response to interferon therapy in chronic hepatitis C. Studies on viral genotype and induction of 2',5'-oligoadenylate synthetase in the liver and peripheral blood cells.

Grandér D, Hultcrantz R, Weiland O, Xu B, Sangfelt O, Björklund AC, Befrits R, Björkholm M, Gruber A, Kinnman N, Reichard O, Widell A, Einhorn S. Grandér D, et al. Among authors: weiland o. Scand J Gastroenterol. 1996 Jun;31(6):604-11. doi: 10.3109/00365529609009135. Scand J Gastroenterol. 1996. PMID: 8789901

9

[Treatment response in chronic hepatitis C. Content of virus in serum is decisive for the outcome].

Weiland O, Danielsson A, Lööf L. Weiland O, et al. Lakartidningen. 1998 Jan 7;95(1-2):40-3. Lakartidningen. 1998. PMID: 9458644 Review. Swedish.

10

Lamivudine and famciclovir combination therapy with or without addition of interferon-alpha-2b for HBeAg-positive chronic hepatitis B: a pilot study.

Sangfelt P, Uhnoo I, Hollander A, Lindh G, Weiland O. Sangfelt P, et al. Among authors: weiland o. Scand J Infect Dis. 2002;34(7):505-11. doi: 10.1080/00365540110080764. Scand J Infect Dis. 2002. PMID: 12195876 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

263 results

Search Page

Filters